PLX

PROTALIX BIOTHER
AMEX

Real-time Quotes | Nasdaq Last Sale

3.870
+0.010
+0.26%
Closed 16:00 02/21 EST
OPEN
3.820
PREV CLOSE
3.820
HIGH
3.970
LOW
3.820
VOLUME
32.55K
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
1.700
MARKET CAP
57.42M
P/E (TTM)
-0.2392
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PLX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PLX stock price target is 20.50 with a high estimate of 30.00 and a low estimate of 11.00.

EPS

PLX News

More
  • Protalix Biotherapeutics (PLX) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 3d ago
  • Protalix BioTherapeutics, Inc.'s (NYSEMKT:PLX) Profit Outlook
  • Simply Wall St. · 02/11 15:52
  • Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium 2020
  • PR Newswire · 02/10 21:05
  • Key events next week - healthcare
  • Seeking Alpha - Article · 02/07 14:47

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
More

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.